St. Jude looks beyond blood pressure for benefits of renal denervation

February 15, 2013 by MassDevice staff

Medical device company St. Jude Medical launches a landmark study of its Enlightn renal denervation in order to find out whether the nerve ablating treatment has unexpected health benefits beyond lowering high blood pressure.

St. Jude Medical's EnliGHTen renal denervation system

St. Jude Medical (NYSE:STJ) is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.